Esperion Therapeutics
ESPR
ESPR
124 hedge funds and large institutions have $104M invested in Esperion Therapeutics in 2023 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 30 increasing their positions, 37 reducing their positions, and 61 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
20% less capital invested
Capital invested by funds: $129M → $104M (-$25.5M)
24% less funds holding
Funds holding: 164 → 124 (-40)
62% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 61
Holders
124
Holding in Top 10
2
Calls
$2.51M
Puts
$1.41M
Top Buyers
| 1 | +$7.66M | |
| 2 | +$4.09M | |
| 3 | +$1.91M | |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$1.24M |
| 5 |
MAM
Monaco Asset Management
Monaco
|
+$767K |
Top Sellers
| 1 | -$6.61M | |
| 2 | -$4.89M | |
| 3 | -$2.23M | |
| 4 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
-$1.64M |
| 5 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$1.5M |